GAUGUIN: Higher Obinutuzumab Dose Shows Promise in Non-Hodgkin Lymphoma

The phase II portion of the GAUGUIN study found promising activity with the anti-CD20 antibody obinutuzumab in patients with relapsed or refractory indolent NHL.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news